{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:24:02Z","timestamp":1794565442374,"version":"4.9.1"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.atherosclerosis.2025.120551","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:18:29Z","timestamp":1760743109000},"page":"120551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease"],"prefix":"10.1016","volume":"411","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-445X","authenticated-orcid":false,"given":"L\u00e6rke Kristine","family":"Kyhl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge Gr\u00f8nne","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tybj\u00e6rg-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sune Fallgaard","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib2","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","author":"Younossi","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.120551_bib3","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the Most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120551_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20294","article-title":"Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019","volume":"3","author":"Wong","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120551_bib6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib8","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"Alexander","year":"2019","journal-title":"Bmj"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2025.120551_bib9","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American heart association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"9733","key":"10.1016\/j.atherosclerosis.2025.120551_bib10","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120551_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"issue":"10060","key":"10.1016\/j.atherosclerosis.2025.120551_bib13","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/S0140-6736(16)31134-5","article-title":"A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the lancet commission on hypertension","volume":"388","author":"Olsen","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120551_bib14","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"7935","key":"10.1016\/j.atherosclerosis.2025.120551_bib15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-022-05398-2","article-title":"A multinational Delphi consensus to end the COVID-19 public health threat","volume":"611","author":"Lazarus","year":"2022","journal-title":"Nature"},{"issue":"10290","key":"10.1016\/j.atherosclerosis.2025.120551_bib16","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120551_bib17","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-pathol-121808-102132","article-title":"Nonalcoholic fatty liver disease: pathology and pathogenesis","volume":"5","author":"Tiniakos","year":"2010","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120551_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120551_bib21","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jhep.2023.08.008","article-title":"Progression of non-alcoholic fatty liver disease and long-term outcomes: a nationwide paired liver biopsy cohort study","volume":"79","author":"Simon","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120551_bib23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib24","article-title":"Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight","volume":"10","year":"2021","journal-title":"eLife"},{"issue":"28","key":"10.1016\/j.atherosclerosis.2025.120551_bib25","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.3748\/wjg.v20.i28.9330","article-title":"Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations","volume":"20","author":"Mili\u0107","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib26","series-title":"National institute for health and care excellence: guidelines. non-alcoholic fatty liver disease: assessment and management","year":"2016"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13098-024-01571-x","article-title":"Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus","volume":"17","author":"Hu","year":"2025","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120551_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.12282","article-title":"Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population","volume":"34","author":"Chon","year":"2014","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2023.05.015","article-title":"High fat in blood and body and increased risk of clinically diagnosed non-alcoholic fatty liver disease in 105,981 individuals","volume":"376","author":"Kyhl","year":"2023","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1467-789X.2004.00144.x","article-title":"Obesity as a disease: no lightweight matter","volume":"5","author":"Conway","year":"2004","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1210\/jc.2015-3444","article-title":"Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies","volume":"101","author":"Loomis","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00535-012-0650-8","article-title":"Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study","volume":"48","author":"Miyake","year":"2013","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/liv.12454","article-title":"Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects","volume":"34","author":"Kim","year":"2014","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3892\/etm.2013.1090","article-title":"Association between metabolic syndrome and the development of non-alcoholic fatty liver disease","volume":"6","author":"Wang","year":"2013","journal-title":"Exp Ther Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00125-018-4787-8","article-title":"Metabolic health in normal-weight and obese individuals","volume":"62","author":"Schulze","year":"2019","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120551_bib40","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1464-5491.2011.03503.x","article-title":"Impact of increased visceral and cardiac fat on cardiometabolic risk and disease","volume":"29","author":"Sironi","year":"2012","journal-title":"Diabet Med"},{"issue":"7121","key":"10.1016\/j.atherosclerosis.2025.120551_bib41","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib42","series-title":"Waist circumference and waist-hip ratio","year":"2008"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2025.120551_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/nu14142994","article-title":"Cutoff points of waist circumference for predicting incident non-alcoholic fatty liver disease in middle-aged and older Korean adults","volume":"14","author":"Lee","year":"2022","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ajcn\/79.3.379","article-title":"Waist circumference and not body mass index explains obesity-related health risk","volume":"79","author":"Janssen","year":"2004","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120551_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/nu15020257","article-title":"Waist circumference is an essential factor in predicting insulin resistance and early detection of metabolic syndrome in adults","volume":"15","author":"Ram\u00edrez-Manent","year":"2023","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2015.02.049","article-title":"Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study","volume":"240","author":"Zhang","year":"2015","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120551_bib47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120551_bib48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jacl.2015.12.026","article-title":"Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol","volume":"10","author":"Wu","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12944-019-1104-6","article-title":"Correlation of triglyceride to high-density lipoprotein cholesterol ratio with nonalcoholic fatty liver disease among the non-obese Chinese population with normal blood lipid levels: a retrospective cohort research","volume":"18","author":"Chen","year":"2019","journal-title":"Lipids Health Dis"},{"issue":"10467","key":"10.1016\/j.atherosclerosis.2025.120551_bib50","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","author":"Zhou","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120551_bib51","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/dc10-2229","article-title":"Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study","volume":"34","author":"Williamson","year":"2011","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120551_bib52","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.atherosclerosis.2025.120551_bib53","doi-asserted-by":"crossref","first-page":"s49","DOI":"10.2337\/dc23-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.120551_bib54","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/liv.13185","article-title":"Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?","volume":"36","author":"Valenti","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111648","article-title":"Epidemiology of NAFLD - focus on diabetes","volume":"210","author":"Younossi","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"7503","key":"10.1016\/j.atherosclerosis.2025.120551_bib56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib57","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2337\/diabetes.54.3.603","article-title":"Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes","volume":"54","author":"Petersen","year":"2005","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib58","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120551_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MED.0000000000000464","article-title":"Dyslipidemia in nonalcoholic fatty liver disease","volume":"26","author":"Amor","year":"2019","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12944-018-0848-8","article-title":"Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study","volume":"17","author":"Wang","year":"2018","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120551_bib61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2013.01.022","article-title":"Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis","volume":"227","author":"DeFilippis","year":"2013","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120551_bib62","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jc.2015-3111","article-title":"Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD","volume":"101","author":"Bril","year":"2016","journal-title":"J Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib63","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz265","article-title":"Low high-density lipoprotein cholesterol to monitor long-term average increased triglycerides","volume":"105","author":"Langsted","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib64","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41371-022-00686-w","article-title":"Association between hypertension and nonalcoholic fatty liver disease: a cross-sectional and meta-analysis study","volume":"37","author":"Huang","year":"2023","journal-title":"J Hum Hypertens"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019974","article-title":"Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey","volume":"8","author":"Hu","year":"2018","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib66","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0000000000002299","article-title":"Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis","volume":"34","author":"Ciardullo","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120551_bib67","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.gastro.2020.04.048","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French nationwide NASH-CO study","volume":"159","author":"Nabi","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib68","series-title":"NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects","first-page":"1460","author":"Sliz","year":"2018"},{"issue":"130","key":"10.1016\/j.atherosclerosis.2025.120551_bib69","first-page":"422","article-title":"High-sensitivity C-reactive protein is a strong predictor of non-alcoholic fatty liver disease","volume":"61","author":"Yeniova","year":"2014","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120551_bib70","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.amjms.2024.01.022","article-title":"ALT poorly predicts Nonalcoholic Fatty Liver Disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult national health and nutrition examination survey 2017-2018","volume":"367","author":"Condon","year":"2024","journal-title":"Am J Med Sci"},{"issue":"Suppl","key":"10.1016\/j.atherosclerosis.2025.120551_bib71","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.120551_bib72","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00439-013-1294-3","article-title":"Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan","volume":"132","author":"Kitamoto","year":"2013","journal-title":"Hum Genet"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.120551_bib73","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib74","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120551_bib75","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","author":"Stender","year":"2017","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib76","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcmgh.2018.07.004","article-title":"Micronutrients in nonalcoholic fatty liver disease pathogenesis","volume":"6","author":"Pickett-Blakely","year":"2018","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.120551_bib77","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/S2542-5196(18)30170-0","article-title":"The global nutrient database: availability of macronutrients and micronutrients in 195 countries from 1980 to 2013","volume":"2","author":"Schmidhuber","year":"2018","journal-title":"Lancet Planet Health"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib78","article-title":"Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy","volume":"27","author":"Nakamura","year":"2024","journal-title":"J Pharm Pharmaceut Sci"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib79","doi-asserted-by":"crossref","first-page":"E578","DOI":"10.1152\/ajpendo.00093.2009","article-title":"The randle cycle revisited: a new head for an old hat","volume":"297","author":"Hue","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/nu13010159","article-title":"Regulation of postabsorptive and postprandial glucose metabolism by insulin-dependent and insulin-independent mechanisms: an integrative approach","volume":"13","author":"Dimitriadis","year":"2021","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.2040-4603.2018.tb00008.x","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr Physiol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib82","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/obr.12143","article-title":"Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule","volume":"15","author":"Heymsfield","year":"2014","journal-title":"Obes Rev"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib83","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbalip.2009.12.006","article-title":"Adipose tissue expandability, lipotoxicity and the metabolic Syndrome--an allostatic perspective","volume":"1801","author":"Virtue","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib84","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib85","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/CIRCULATIONAHA.111.087213","article-title":"Energy balance and obesity","volume":"126","author":"Hill","year":"2012","journal-title":"Circulation"},{"issue":"181","key":"10.1016\/j.atherosclerosis.2025.120551_bib86","doi-asserted-by":"crossref","first-page":"385","DOI":"10.24976\/Discov.Med.202436181.36","article-title":"Artesunate inhibits lipid accumulation and inflammation by regulating the NLRP3 inflammasome in nonalcoholic fatty liver disease","volume":"36","author":"Sun","year":"2024","journal-title":"Discov Med"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2025.120551_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib88","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Investig"},{"issue":"31","key":"10.1016\/j.atherosclerosis.2025.120551_bib89","doi-asserted-by":"crossref","first-page":"12587","DOI":"10.1073\/pnas.0705408104","article-title":"The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome","volume":"104","author":"Petersen","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.120551_bib90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11892-018-1101-6","article-title":"Pathogenesis of lipid disorders in insulin resistance: a brief review","volume":"18","author":"Bjornstad","year":"2018","journal-title":"Curr Diab Rep"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120551_bib91","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0000000000001191","article-title":"Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?","volume":"30","author":"Oikonomou","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib92","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ki.2014.392","article-title":"Insulin resistance and hypertension: new insights","volume":"87","author":"Soleimani","year":"2015","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib93","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in obesity: mechanisms and potential targets","volume":"5","author":"Klop","year":"2013","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.120551_bib94","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib95","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111s","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib96","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol Commun"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2025.120551_bib97","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib98","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep4.1155","article-title":"Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis","volume":"2","author":"Zhou","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib99","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120551_bib100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","article-title":"Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: mendelian randomization and meta-analysis of 279 013 individuals","volume":"39","author":"Lauridsen","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib101","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1038\/s41467-024-49224-x","article-title":"PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein","volume":"15","author":"Johnson","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib102","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib103","doi-asserted-by":"crossref","first-page":"11124","DOI":"10.1038\/s41598-019-47687-3","article-title":"Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis","volume":"9","author":"Liu","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120551_bib104","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/01.CIR.67.5.968","article-title":"Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the framingham heart study","volume":"67","author":"Hubert","year":"1983","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120551_bib106","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41366-023-01408-z","article-title":"Association of obesity with cardiovascular disease in the absence of traditional risk factors","volume":"48","author":"Luo","year":"2024","journal-title":"Int J Obes"},{"issue":"39","key":"10.1016\/j.atherosclerosis.2025.120551_bib107","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib108","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00125-012-2707-x","article-title":"Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus","volume":"56","author":"Sch\u00f6ttker","year":"2013","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.120551_bib109","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jama.2014.1873","article-title":"Glycated hemoglobin measurement and prediction of cardiovascular disease","volume":"311","author":"Di Angelantonio","year":"2014","journal-title":"JAMA, J Am Med Assoc"},{"issue":"13\u201314","key":"10.1016\/j.atherosclerosis.2025.120551_bib110","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.clinbiochem.2009.05.018","article-title":"Hepatic insulin resistance, metabolic syndrome and cardiovascular disease","volume":"42","author":"Meshkani","year":"2009","journal-title":"Clin Biochem"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2025.120551_bib111","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes","volume":"140","author":"Marston","year":"2019","journal-title":"Circulation"},{"issue":"9943","key":"10.1016\/j.atherosclerosis.2025.120551_bib112","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120551_bib113","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jsps.2023.04.002","article-title":"Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC\/AHA guidelines","volume":"31","author":"Matyori","year":"2023","journal-title":"Saudi Pharm J"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.120551_bib114","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1161\/hq1201.100259","article-title":"Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia","volume":"21","author":"Stein","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120551_bib115","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database","volume":"51","author":"Barter","year":"2010","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.120551_bib116","first-page":"793","article-title":"A short history of blood pressure measurement","volume":"70","author":"Booth","year":"1977","journal-title":"Proc Roy Soc Med"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120551_bib117","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","article-title":"Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis","volume":"10","author":"Nazarzadeh","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120495","article-title":"Understanding MASLD - from molecular pathogenesis to cardiovascular risk: a concise review for the clinical cardiologist","volume":"409","author":"Ratti","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.993633","article-title":"Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: implications for disease progression and mechanistic insights","volume":"9","author":"Lee","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0000000000000429","article-title":"Remnant lipoproteins","volume":"28","author":"Varbo","year":"2017","journal-title":"Curr Opin Lipidol"},{"issue":"15\u201316","key":"10.1016\/j.atherosclerosis.2025.120551_bib121","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.cca.2011.04.018","article-title":"Postprandial lipoprotein metabolism: VLDL vs chylomicrons","volume":"412","author":"Nakajima","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"34","key":"10.1016\/j.atherosclerosis.2025.120551_bib122","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstr\u00f6m","year":"2021","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2025.120551_bib123","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-Containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.119094","article-title":"VLDL triglycerides and cholesterol in non-alcoholic fatty liver disease and myocardial infarction","volume":"401","author":"Kyhl","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol Metabol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib126","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.120551_bib127","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2019.07.037","article-title":"Impact of LDL cholesterol on microvascular versus macrovascular disease: a mendelian randomization study","volume":"74","author":"Emanuelsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib128","series-title":"Endotext. South dartmouth (MA): MDText.com, inc. Copyright \u00a9 2000-2025","article-title":"Introduction to lipids and lipoproteins","author":"Feingold","year":"2000"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2025.120551_bib129","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease","volume":"76","author":"Casta\u00f1er","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/clinchem\/hvaa290","article-title":"Very low-density lipoprotein cholesterol may mediate a substantial component of the effect of obesity on myocardial infarction risk: the copenhagen general population study","volume":"67","author":"Johansen","year":"2021","journal-title":"Clin Chem"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120551_bib131","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.tem.2011.04.007","article-title":"Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance","volume":"22","author":"Choi","year":"2011","journal-title":"Trends Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120551_bib132","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41440-023-01558-7","article-title":"Remnant cholesterol and risk of incident hypertension: a population-based prospective cohort study","volume":"47","author":"Guo","year":"2024","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib133","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.120551_bib134","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"34","key":"10.1016\/j.atherosclerosis.2025.120551_bib135","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.atherosclerosis.2025.120551_bib136","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target populations for novel triglyceride-lowering therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120551_bib137","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120551_bib138","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: october 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib139","article-title":"What is the pipeline for future medications for obesity?","author":"Melson","year":"2024","journal-title":"Int J Obes"},{"key":"10.1016\/j.atherosclerosis.2025.120551_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metab, Clin Exp"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120551_bib141","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.120551_bib142","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib143","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jacl.2023.04.007","article-title":"APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia","volume":"17","author":"Prohaska","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120551_bib144","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.31687","article-title":"Nonalcoholic steatohepatitis: current thinking from the division of hepatology and nutrition at the food and drug administration","volume":"73","author":"Anania","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120551_bib145","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025014492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025014492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:31:41Z","timestamp":1783690301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025014492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":145,"alternative-id":["S0021915025014492"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120551","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120551"}}